2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
5
Healthy Participants
5
Breast Neoplasms
5
Prostatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Venous Thromboembolism
2
Solid Tumor, Adult
2
Neoplasm Metastasis
2
Healthy Volunteers
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Cardiovascular Diseases
2
cMET-dysregulated Advanced Solid Tumors
1
Venous Thrombosis
1
TP53 Y220C Mutation
1
Stroke
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Pulmonary Embolism
1
Prostatic Neoplasms, Castration-Resistant
1
Precancerous Conditions
1
Peripheral Nervous System Diseases
1
Pain
1
Ovarian Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Interventions
Doxorubicin
25
Gemcitabine
16
Trabectedin
12
Ifosfamide
12
Radiotherapy
11
Docetaxel
10
Dacarbazine
8
pazopanib
7
Nivolumab
6
Specimen Handling
5
Biopsy
5
liposomal doxorubicin
4
Temozolomide
4
pembrolizumab
3
Sunitinib
3
Sorafenib
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
rucaparib
2
pegfilgrastim
2
olaratumab
2
eribulin
2
durvalumab
2
cixutumumab
2
cemiplimab
2
brostallicin
2
belinostat
2
avelumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leiomyosarcoma
×
Rosuvastatin Calcium
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled